Posted On: 02/22/2014 8:52:22 AM
Post# of 5066
Just thought I'd toss around what seems to be a forgotten value for BMSN. We all know by now the divy of Regen shares is basically going to act as a multiplayer when the shares hit the market. When the record date is given we will receive our shares but will have to wait on the FINRA for a trading symbol for at least a month. So we get our shares and while we are waiting to trade them, hemaxellerate will be approved and dcellvax ind application submitted sending BMSN pps rocketing north. The great part is the Regen PPS will be determined by the BMSN PPS at the time they hit the market. So let's say BMSN lands on .03 well that means Regen PPS should trade at 3.00 not bad for free shares (1 regen share for every 140 BMSN shares on the record date which could be any day now). Here's the kicker... Once the Regen shares hit the market this is instant value for BMSN as they own 58% of Regen. I know crazy right... It's almost as if Koos knows exactly what he's doing and is creating insane shareholder value. Huuuuge value.
Now here's a little something that hasn't been talked about or included in the BMSN valuation for a while so thought I'd toss out a little reminder. ENTB has been extremely quite but has a 10 dog study still in the works and I have this feeling we are about to hear a lot more about it in the very near future. The treatment they are developing is no joke and is worth mega bucks.
Medistem to Host Investor Update Conference Call
SAN DIEGO, CA–(Marketwired – Jul 19, 2013) Q: What about the 10 dog arthritis study?
A: This was a study where we licensed veterinary use of the ERC to Cook General Biotechnology
together with Entest utilizing canine ERCs. Cook General Biotechnology, together with Entest, they
launched a 10 dog study canine ERCs. The results have not been published yet. The study was being
conducted at a private veterinary clinic in Santa Barbara under an INAD that is held by Cook General
Biotechnology. Medistem did support the study actively, provided the cells to the study and right now
we are still in the process of analyzing the data. Of the 10 dogs, 9 have been successfully dosed and the
follow-up data is in the process of being analyzed.
Now here's a little something that hasn't been talked about or included in the BMSN valuation for a while so thought I'd toss out a little reminder. ENTB has been extremely quite but has a 10 dog study still in the works and I have this feeling we are about to hear a lot more about it in the very near future. The treatment they are developing is no joke and is worth mega bucks.
Medistem to Host Investor Update Conference Call
SAN DIEGO, CA–(Marketwired – Jul 19, 2013) Q: What about the 10 dog arthritis study?
A: This was a study where we licensed veterinary use of the ERC to Cook General Biotechnology
together with Entest utilizing canine ERCs. Cook General Biotechnology, together with Entest, they
launched a 10 dog study canine ERCs. The results have not been published yet. The study was being
conducted at a private veterinary clinic in Santa Barbara under an INAD that is held by Cook General
Biotechnology. Medistem did support the study actively, provided the cells to the study and right now
we are still in the process of analyzing the data. Of the 10 dogs, 9 have been successfully dosed and the
follow-up data is in the process of being analyzed.
(0)
(0)Scroll down for more posts ▼
